Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"Does the company still own Kevetrin......Leo has never provided us with that answer."
It does, according to Google Patents.
The patent, which is the same patent that was at the center of the Aruda controversy, was assigned to Cellceutix and is still active. It expires in 2030.

Commander Leo has said "In September 2022, the Company, after a review of its assets and opportunities, discontinued its Kevetrin program in oncology due to reduced patent life and the added research and development costs for oral delivery of the compound."
In case it isn't obvious, discontinuing the program is not the same as no longer owning the drug.